Nektar Therapeutics (NKTR) closed at $37.27 on November 13, 2026, up 0.1% from the previous close, on volume of 666,287 shares (30-day average 933,986).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Diagonal Call Spread | 19-Feb-27 : 21-Jan-2870 : 65 C | 400 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Nektar Therapeutics Earnings Call Signals Clinical Momentum
TipRanks (Sat, 14-Nov 10:21 PM ET)
Leerink Partners Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)
TipRanks (Fri, 13-Nov 9:37 AM ET)
Piper Sandler Keeps Their Buy Rating on Nektar Therapeutics (NKTR)
TipRanks (Fri, 13-Nov 9:07 AM ET)
Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)
TipRanks (Fri, 13-Nov 9:07 AM ET)
Nektar Therapeutics GAAP EPS of -$1.63 beats by $0.44, revenue of $9.39M misses by $1.01M
Seeking Alpha News (Thu, 12-Nov 4:17 PM ET)
Nektar Therapeutics Announces Third Quarter 2026 Financial Results
PRNewswire (Thu, 12-Nov 4:15 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Nektar Therapeutics to Participate in Two Investor Conferences in November
PRNewswire (Wed, 11-Nov 4:15 PM ET)
PRNewswire (Tue, 27-Oct 6:01 PM ET)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 23-Oct 4:16 PM ET)
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Nektar Therapeutics trades on the NASDAQ stock market under the symbol NKTR.
As of November 13, 2026, NKTR stock price climbed to $37.27 with 666,287 million shares trading.
NKTR has a beta of 1.04, meaning it tends to be more sensitive to market movements. NKTR has a correlation of 0.02 to the broad based SPY ETF.
NKTR has a market cap of $1.27 billion. This is considered a Small Cap stock.
Last quarter Nektar Therapeutics reported $9 million in Revenue and -$1.63 earnings per share. This fell short of revenue expectation by $-994,136 and exceeded earnings estimates by $.46.
In the last 3 years, NKTR traded as high as $109.00 and as low as $6.34.
The top ETF exchange traded funds that NKTR belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
NKTR has underperformed the market in the last year with a price return of -30.9% while the SPY ETF gained +13.4%. NKTR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.9% and -4.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
NKTR support price is $36.04 and resistance is $38.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTR shares will trade within this expected range on the day.